ir_header
Current stock value

Last updated on Dec 19, 2014 4:00 PM ET

NASDAQ : SPHS 0.45   
- 0.04
  
8.16%

Fact Sheet

PDF Download the Sophiris Fact Sheet


Investor Presentation

PDF Download the Sophiris Investor Presentation


Investors

Sophiris Bio Inc. (NASDAQ: SPHS) is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), which it believes is an unsatisfied market with significant market potential. Sophiris’ lead candidate for BPH, PRX302, is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Sophiris has completed enrollment in a Phase III (PLUS-1) clinical study using PRX302 for the treatment of symptoms of BPH.

View all »   RSSRecent Releases

Dec 15, 2014
Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia

Nov 25, 2014
Sophiris Bio to Present at the 26th Annual Piper Jaffray Healthcare Conference